Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqitongluo is a Traditional Chinese Medicine (TCM) hospital preparation developed by the Yunnan Provincial Hospital of Traditional Chinese Medicine, specifically indicated for the treatment of diabetic peripheral neuropathy (DPN). The formula is based on the therapeutic principle of 'replenishing Qi and dredging collaterals' to address the underlying pathology of Qi deficiency and blood stasis common in diabetic patients. It typically consists of a complex mixture of herbal ingredients, including *Astragalus membranaceus* (Huangqi), *Pueraria lobata* (Gegen), and *Salvia miltiorrhiza* (Danshen). Pharmacologically, Yiqitongluo is designed to improve peripheral microcirculation, enhance nerve conduction velocity, and provide neuroprotection by reducing oxidative stress and inhibiting the polyol pathway and the formation of advanced glycation end-products (AGEs). It is primarily administered in granule or capsule form within the hospital's clinical practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yiqitongluo.